DRMA — Dermata Therapeutics, Inc.
Is DRMA overbought or oversold? Here is the current MarketMoodz read.
Dermata Therapeutics, Inc. (DRMA) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.60. The rating moved from Strong Oversold to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$0.60
- Last changeMoved from Strong Oversold to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Dermata Therapeutics, Inc. (DRMA) is a small-cap, dermatology-focused clinical company with typical binary upside from trial readouts or partnership activity but substantial uncertainty due to limited public financial detail. The current market environment favors large-cap pharma, which may constrain capital flows to microcap biotech names. Primary drivers are clinical progress, potential business-development interest, and financing dynamics; primary risks are cash runway and dilution, clinical/regulatory failure, low liquidity, and competitive pressure. Given sparse publicly-available filings and social commentary in the provided data, visibility into near-term fundamentals is limited and outcomes are binary.
Key factors
- Early-stage dermatology-focused pipeline with potential clinical-readout catalysts (typical value driver for small-cap biotech).
- Limited publicly-available financial disclosures and EDGAR comparisons in the provided data set, increasing uncertainty around runway and cash flow.
- Market environment showing risk-on participation for growth names but strong investor preference toward large-cap pharma, which may reduce capital flows to microcap biotechs.
- Sector-level headwinds around convertible-debt dilution risk for mid/small-cap biotechs that could pressure share price if financing is required.
- Potential upside from licensing, partnership interest, or positive trial data which can materially re-rate a small-cap clinical company.
Risks
- Short cash runway or need for dilutive financing (equity or convertible instruments) with no recent EDGAR filing detail provided.
- Clinical or regulatory setbacks in development programs, which would significantly reduce valuation for an early-stage biotech.
- Low liquidity and high share-price volatility typical of penny stocks, amplifying downside on negative news or broader risk-off flows.
- Competition from larger dermatology and specialty pharma companies with deeper commercial and regulatory resources.
- Macro and sector dynamics favoring large-cap defensive pharma could limit institutional interest and secondary offering pricing.
- Lack of social/research commentary and limited public information increases model risk and execution uncertainty.
See today's live rating, score and targets
Members see the live hourly rating for DRMA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.